APGE Stock — Apogee Therapeutics, Inc.: Metrics

Market overview

2 metrics

Share price

$135.07

Market cap

$10.22B

Price action

19 metrics

Price change (1W)

+0.2%

Price change (30D)

+0.7%

Price change (3M)

+71.6%

Price change (6M)

+97.2%

Price change (YTD)

+79.0%

Price change (1Y)

+271.4%

Trailing year

Price change (5Y)

—

52-week high

$135.08

52-week low

$36.53

Change from 52-week high

+0.0%

Change from 52-week low

+269.8%

Annualized volatility

69.6%

Beta

0.9

RSI (14D)

79.0

Price vs SMA 50

+0.7%

Price vs SMA 200

+47.4%

Avg volume (3M)

2.70M

Relative volume

0.4

Average dollar volume

$349.36M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

75.69M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

—

P / book

—

FCF yield

—

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-2.9%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2026-05-27

Profitability

9 metrics

Gross margin

—

Operating margin

—

Trailing 12 months

Net margin

—

Gross profit (TTM)

—

Operating profit (TTM)

−$328.11M

Net income (TTM)

−$294.37M

Trailing 12 months

Diluted EPS (TTM)

$-4.34

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

—

Growth

11 metrics

Revenue growth YoY

—

Year over year

Net income growth YoY

—

Revenue (TTM)

—

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+29.1%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

—

Return on assets

-22.0%

Debt / equity

—

Current ratio

26.4

EBITDA (TTM)

—

Free cash flow (TTM)

—

Quick ratio

26.4

Interest coverage

—

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

$971.93M

Latest balance sheet

Cash & equivalents

$105.57M

Total assets

$1.34B

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$243.89M

Capital expenditures (TTM)

$5.15M

R&D (TTM)

$240.74M

SG&A (TTM)

—

Stock compensation (TTM)

$57.62M

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

292

13F filer change QoQ

+62

Institutional ownership

91.2%

Short interest

3 metrics

Short interest

5.6%

Latest settlement · 3.2 days to cover

Days to cover

3.2d

Short-squeeze score

61 / 100

Insider activity

2 metrics

Net insider buying (90D)

−$19.91M

Insider-sentiment score

—

Risk flags

1 metrics

Going concern

—

APGE · Apogee Therapeutics, Inc.

APGE metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search